NTLA

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.

Wall Street analysts forecast NTLA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTLA is 15.97 USD with a low forecast of 4.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Intellia Therapeutics Inc revenue for the last quarter amounts to 13.78M USD, increased 51.27 % YoY.

Intellia Therapeutics Inc. EPS for the last quarter amounts to -0.92 USD, decreased -31.34 % YoY.

Intellia Therapeutics Inc (NTLA) has 403 emplpoyees as of December 16 2025.

Today NTLA has the market capitalization of 1.06B USD.